Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients

H. C. Dearden; R. Mason; B. Nguyen; J. A. Soon; J. L. Smith; M. Randhawa; A. Mant; L. Warburton; S. Lo; T. Meniawy; A. Guminski; P. Parente; S. Ali; A. Haydon; G. V. Long; M. S. Carlino; M. Millward; V. G. Atkinson; A. M. Menzies

doi:10.1093/annonc/mdy289.012

Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients

H. C. Dearden, R. Mason, B. Nguyen, J. A. Soon, J. L. Smith, M. Randhawa, A. Mant, L. Warburton, S. Lo, T. Meniawy, A. Guminski, P. Parente, S. Ali, A. Haydon, G. V. Long, M. S. Carlino, M. Millward, V. G. Atkinson, A. M. Menzies

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	448-448
Number of pages	1
Journal	Annals of Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy289.012
Publication status	Published - Oct 2018
Externally published	Yes
Event	43rd ESMO Congress (ESMO) - Munich, Germany Duration: 19 Oct 2018 → 23 Oct 2018

Access to Document

10.1093/annonc/mdy289.012Licence: Other

Cite this

Dearden, H. C., Mason, R., Nguyen, B., Soon, J. A., Smith, J. L., Randhawa, M., Mant, A., Warburton, L., Lo, S., Meniawy, T., Guminski, A., Parente, P., Ali, S., Haydon, A., Long, G. V., Carlino, M. S., Millward, M., Atkinson, V. G., & Menzies, A. M. (2018). Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients. Annals of Oncology, 29, 448-448. https://doi.org/10.1093/annonc/mdy289.012

@article{505be0839e684a52a008aeb2e95692fa,

title = "Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients",

author = "Dearden, {H. C.} and R. Mason and B. Nguyen and Soon, {J. A.} and Smith, {J. L.} and M. Randhawa and A. Mant and L. Warburton and S. Lo and T. Meniawy and A. Guminski and P. Parente and S. Ali and A. Haydon and Long, {G. V.} and Carlino, {M. S.} and M. Millward and Atkinson, {V. G.} and Menzies, {A. M.}",

year = "2018",

month = oct,

doi = "10.1093/annonc/mdy289.012",

language = "English",

volume = "29",

pages = "448--448",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "43rd ESMO Congress (ESMO) ; Conference date: 19-10-2018 Through 23-10-2018",

}

Dearden, HC, Mason, R, Nguyen, B, Soon, JA, Smith, JL, Randhawa, M, Mant, A, Warburton, L, Lo, S, Meniawy, T, Guminski, A, Parente, P, Ali, S, Haydon, A, Long, GV, Carlino, MS, Millward, M, Atkinson, VG & Menzies, AM 2018, 'Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients', Annals of Oncology, vol. 29, pp. 448-448. https://doi.org/10.1093/annonc/mdy289.012

TY - JOUR

T1 - Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients

AU - Dearden, H. C.

AU - Mason, R.

AU - Nguyen, B.

AU - Soon, J. A.

AU - Smith, J. L.

AU - Randhawa, M.

AU - Mant, A.

AU - Warburton, L.

AU - Lo, S.

AU - Meniawy, T.

AU - Guminski, A.

AU - Parente, P.

AU - Ali, S.

AU - Haydon, A.

AU - Long, G. V.

AU - Carlino, M. S.

AU - Millward, M.

AU - Atkinson, V. G.

AU - Menzies, A. M.

PY - 2018/10

Y1 - 2018/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uwapure5-25&SrcAuth=WosAPI&KeyUT=WOS:000459277303027&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1093/annonc/mdy289.012

DO - 10.1093/annonc/mdy289.012

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 29

SP - 448

EP - 448

JO - Annals of Oncology

JF - Annals of Oncology

T2 - 43rd ESMO Congress (ESMO)

Y2 - 19 October 2018 through 23 October 2018

ER -

Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients

Access to Document

Other files and links

Cite this